



Press release

## €1.4 million capital increase by Acticor Biotech

**Funding used to step up development of its first-in-class drug candidate for the emergency treatment of strokes**

**Paris, 11 July 2016** – Acticor Biotech, biotechnology company which is developing an anti-thrombotic agent without bleeding risk for the emergency treatment of ischemic strokes, has just completed a €1.4 million capital increase. The funds were raised from investors via the Anaxago crowdfunding platform (€740,000), from research association ARMESA (€500,000) and from business angels (€170,000).

Acticor Biotech's ACT-017 drug candidate represents a **major innovation in the emergency treatment of ischemic strokes**. It is a first-in-class candidate that inhibits a new target protein, the glycoprotein VI, which is specifically responsible for the growth of blood clots during a stroke. ACT-017 is intended to be used alone or in combination with Alteplase®, the only emergency treatment currently available, which is given to fewer than 10% of patients in the four and a half hours after the first symptoms appearing.

The capital increase will enable Acticor Biotech to continue pre-clinical development and produce initial batches of ACT-017.

Gilles Avenard, CEO of Acticor Biotech, said *"the emergency treatment of ischemic strokes represents a major medical need, since over 600,000 patients per year are affected in Europe. The treatment of ischemic strokes, either in combination with Alteplase® or after Alteplase®, must be without bleeding risk. In vitro and in vivo testing of ACT-017 have confirmed results already published, suggesting that we have a drug candidate that will eventually be possible to admin just after the first symptoms appear."*

Joachim Dupont, co-founder of Anaxago and director of Acticor Biotech, said *"this second funding round for Acticor Biotech, organized via our platform, is 30% larger than the first round and provides further validation of the crowdfunding model for the healthcare sector. It shows the interest of investors for Acticor*

*biotech developments in stroke treatment, and their desire to support the development of innovative solutions to major unresolved public health problems."*

**According to the WHO, 23 million people around the world will suffer a stroke in 2030.**

**About Ischemic stroke - <http://acticor-biotech.com/en/stroke/>**

**About ACT-017 - <http://acticor-biotech.com/en/technology/>**

**About ACTICOR-BIOTECH - <http://acticor-biotech.com/>**

**Contacts :**

**Acticor Biotech**

Gilles Avenard - [gilles.avenard@acticor-biotech.com](mailto:gilles.avenard@acticor-biotech.com)

**Contact Presse: NewCap**

Annie-Florence Loyer - [afloyer@newcap.fr](mailto:afloyer@newcap.fr)

01 44 72 00 12 / 06 88 20 35 59

Léa Jacquin – [ljacquin@newcap.fr](mailto:ljacquin@newcap.fr)

01 44 71 20 41